Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000635221 | SCV000756604 | uncertain significance | Familial hemiplegic migraine | 2023-04-12 | criteria provided, single submitter | clinical testing | This missense change has been observed in individual(s) with clinical features of ATP1A2-related conditions (Invitae). This variant is present in population databases (rs757867108, gnomAD 0.003%). This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 298 of the ATP1A2 protein (p.Val298Leu). ClinVar contains an entry for this variant (Variation ID: 529754). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ATP1A2 protein function. |
| Ambry Genetics | RCV002448963 | SCV002682048 | uncertain significance | Inborn genetic diseases | 2018-01-31 | criteria provided, single submitter | clinical testing | The p.V298L variant (also known as c.892G>C), located in coding exon 8 of the ATP1A2 gene, results from a G to C substitution at nucleotide position 892. The valine at codon 298 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |